APO Research
Talk to an analyst

APO RESEARCH · REPORT

Small Molecule Multi-target Angiogenesis Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Small Molecule Multi-target Angiogenesis Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025192 pages

Choose your research edition.

Industry ResearchSmall Molecule Multi-target Angiogenesis Inhibitor Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Small Molecule Multi-target Angiogenesis Inhibitor Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Small Molecule Multi-target Angiogenesis Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor include Chia Tai Tianqing, Teva, Jiangsu Hengrui Pharmaceuticals, TWi Pharmaceuticals, Sanofi, Pfizer, Novartis, Janssen Biotech and Exelixis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Small Molecule Multi-target Angiogenesis Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Small Molecule Multi-target Angiogenesis Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Small Molecule Multi-target Angiogenesis Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Small Molecule Multi-target Angiogenesis Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Company

Chia Tai Tianqing

Teva

Jiangsu Hengrui Pharmaceuticals

TWi Pharmaceuticals

Sanofi

Pfizer

Novartis

Janssen Biotech

Exelixis

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca.

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Type

Apatinib

Axitinib

Anlotinib

Vandetanib

Cabozantinib

Lenvatinib

Pazopanib

Sunitinib

Sorafenib

Other

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Application

Cancer Therapy

Inflammatory and Autoimmune Diseases

Ophthalmic Diseases

Other

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Small Molecule Multi-target Angiogenesis Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Small Molecule Multi-target Angiogenesis Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Small Molecule Multi-target Angiogenesis Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Small Molecule Multi-target Angiogenesis Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Small Molecule Multi-target Angiogenesis Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Small Molecule Multi-target Angiogenesis Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Small Molecule Multi-target Angiogenesis Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends Table 2. Small Molecule Multi-target Angiogenesis Inhibitor Industry Drivers Table 3. Small Molecule Multi-target Angiogenesis Inhibitor Industry Opportunities and Challenges Table 4. Small Molecule Multi-target Angiogenesis Inhibitor Industry Restraints Table 5. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Manufacturers Table 9. Global Small Molecule Multi-target Angiogenesis Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Small Molecule Multi-target Angiogenesis Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Small Molecule Multi-target Angiogenesis Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Small Molecule Multi-target Angiogenesis Inhibitor Manufacturers, Product Type & Application Table 13. Global Small Molecule Multi-target Angiogenesis Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Small Molecule Multi-target Angiogenesis Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Apatinib Table 17. Major Manufacturers of Axitinib Table 18. Major Manufacturers of Anlotinib Table 19. Major Manufacturers of Vandetanib Table 20. Major Manufacturers of Cabozantinib Table 21. Major Manufacturers of Lenvatinib Table 22. Major Manufacturers of Pazopanib Table 23. Major Manufacturers of Sunitinib Table 24. Major Manufacturers of Sorafenib Table 25. Major Manufacturers of Other Table 26. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 28. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2027-2032) & (K Units) Table 29. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2026) Table 30. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2027-2032) Table 31. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 32. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021-2026) & (K Units) Table 33. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2027-2032) & (K Units) Table 34. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2026) Table 35. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2027-2032) Table 36. Major Manufacturers of Cancer Therapy Table 37. Major Manufacturers of Inflammatory and Autoimmune Diseases Table 38. Major Manufacturers of Ophthalmic Diseases Table 39. Major Manufacturers of Other Table 40. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 42. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2027-2032) & (K Units) Table 43. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2026) Table 44. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2027-2032) Table 45. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 46. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021-2026) & (K Units) Table 47. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2027-2032) & (K Units) Table 48. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2026) Table 49. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2027-2032) Table 50. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 51. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2026) & (K Units) Table 52. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021-2026) Table 53. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 54. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 55. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 57. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 58. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 60. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 61. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 63. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 64. South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 65. South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 66. South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 67. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 69. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 70. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021-2026) Table 71. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2027-2032) Table 72. Chia Tai Tianqing Company Information Table 73. Chia Tai Tianqing Business Overview Table 74. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 76. Chia Tai Tianqing Recent Development Table 77. Teva Company Information Table 78. Teva Business Overview Table 79. Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 81. Teva Recent Development Table 82. Jiangsu Hengrui Pharmaceuticals Company Information Table 83. Jiangsu Hengrui Pharmaceuticals Business Overview Table 84. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 86. Jiangsu Hengrui Pharmaceuticals Recent Development Table 87. TWi Pharmaceuticals Company Information Table 88. TWi Pharmaceuticals Business Overview Table 89. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 91. TWi Pharmaceuticals Recent Development Table 92. Sanofi Company Information Table 93. Sanofi Business Overview Table 94. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 96. Sanofi Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 101. Pfizer Recent Development Table 102. Novartis Company Information Table 103. Novartis Business Overview Table 104. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 106. Novartis Recent Development Table 107. Janssen Biotech Company Information Table 108. Janssen Biotech Business Overview Table 109. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 111. Janssen Biotech Recent Development Table 112. Exelixis Company Information Table 113. Exelixis Business Overview Table 114. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 116. Exelixis Recent Development Table 117. Eisai Company Information Table 118. Eisai Business Overview Table 119. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 121. Eisai Recent Development Table 122. Boehringer Ingelheim Company Information Table 123. Boehringer Ingelheim Business Overview Table 124. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 126. Boehringer Ingelheim Recent Development Table 127. Bayer Company Information Table 128. Bayer Business Overview Table 129. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 131. Bayer Recent Development Table 132. AstraZeneca. Company Information Table 133. AstraZeneca. Business Overview Table 134. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 136. AstraZeneca. Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Small Molecule Multi-target Angiogenesis Inhibitor Distributors List Table 140. Small Molecule Multi-target Angiogenesis Inhibitor Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Small Molecule Multi-target Angiogenesis Inhibitor Product Image Figure 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Small Molecule Multi-target Angiogenesis Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Apatinib Image Figure 9. Axitinib Image Figure 10. Anlotinib Image Figure 11. Vandetanib Image Figure 12. Cabozantinib Image Figure 13. Lenvatinib Image Figure 14. Pazopanib Image Figure 15. Sunitinib Image Figure 16. Sorafenib Image Figure 17. Other Image Figure 18. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2032) Figure 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2032) Figure 24. Cancer Therapy Image Figure 25. Inflammatory and Autoimmune Diseases Image Figure 26. Ophthalmic Diseases Image Figure 27. Other Image Figure 28. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 29. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 30. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2032) Figure 31. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 33. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2032) Figure 34. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 36. U.S. Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Canada Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Mexico Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 41. Germany Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. France Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. U.K. Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Italy Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Netherlands Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 48. China Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Japan Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Korea Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. India Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Australia Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2032) Figure 56. Brazil Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 57. South Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Turkey Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Argentina Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 61. UAE Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 62. Egypt Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 63. Chile Small Molecule Multi-target Angiogenesis Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 64. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 66. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2032) & (US$ Million) Figure 67. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2032) & (US$ Million) Figure 69. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2032) & (US$ Million) Figure 71. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2032) & (US$ Million) Figure 73. South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 74. Small Molecule Multi-target Angiogenesis Inhibitor Value Chain Figure 75. Manufacturing Cost Structure Figure 76. Small Molecule Multi-target Angiogenesis Inhibitor Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Apatinib
  • Axitinib
  • Anlotinib
  • Vandetanib
  • Cabozantinib
  • Lenvatinib
  • Pazopanib
  • Sunitinib
  • Sorafenib
  • Other
Applications
  • Cancer Therapy
  • Inflammatory and Autoimmune Diseases
  • Ophthalmic Diseases
  • Other
Companies covered
  • Chia Tai Tianqing
  • Teva
  • Jiangsu Hengrui Pharmaceuticals
  • TWi Pharmaceuticals
  • Sanofi
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Dynamics
  1. 2.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends
  2. 2.2 Small Molecule Multi-target Angiogenesis Inhibitor Industry Drivers
  3. 2.3 Small Molecule Multi-target Angiogenesis Inhibitor Industry Opportunities and Challenges
  4. 2.4 Small Molecule Multi-target Angiogenesis Inhibitor Industry Restraints
3 Small Molecule Multi-target Angiogenesis Inhibitor Market by Manufacturers
  1. 3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Small Molecule Multi-target Angiogenesis Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Small Molecule Multi-target Angiogenesis Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global Small Molecule Multi-target Angiogenesis Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Small Molecule Multi-target Angiogenesis Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Small Molecule Multi-target Angiogenesis Inhibitor Tier 1, Tier 2, and Tier 3
4 Small Molecule Multi-target Angiogenesis Inhibitor Market by Type
  1. 4.1 Small Molecule Multi-target Angiogenesis Inhibitor Type Introduction
  2. 4.1.1 Apatinib
  3. 4.1.2 Axitinib
  4. 4.1.3 Anlotinib
  5. 4.1.4 Vandetanib
  6. 4.1.5 Cabozantinib
  7. 4.1.6 Lenvatinib
  8. 4.1.7 Pazopanib
  9. 4.1.8 Sunitinib
  10. 4.1.9 Sorafenib
  11. 4.1.10 Other
  12. 4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type
  13. 4.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2032)
  15. 4.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021-2032)
  16. 4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type
  17. 4.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2021-2032)
  19. 4.3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021-2032)
5 Small Molecule Multi-target Angiogenesis Inhibitor Market by Application
  1. 5.1 Small Molecule Multi-target Angiogenesis Inhibitor Application Introduction
  2. 5.1.1 Cancer Therapy
  3. 5.1.2 Inflammatory and Autoimmune Diseases
  4. 5.1.3 Ophthalmic Diseases
  5. 5.1.4 Other
  6. 5.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application
  7. 5.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2032)
  9. 5.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021-2032)
  10. 5.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application
  11. 5.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2021-2032)
  13. 5.3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021-2032)
6 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region
  1. 6.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region
  1. 7.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region
  2. 7.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing
  2. 8.1.1 Chia Tai Tianqing Company Information
  3. 8.1.2 Chia Tai Tianqing Business Overview
  4. 8.1.3 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Jiangsu Hengrui Pharmaceuticals
  14. 8.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
  15. 8.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  16. 8.3.3 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  18. 8.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  19. 8.4 TWi Pharmaceuticals
  20. 8.4.1 TWi Pharmaceuticals Company Information
  21. 8.4.2 TWi Pharmaceuticals Business Overview
  22. 8.4.3 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  24. 8.4.5 TWi Pharmaceuticals Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Janssen Biotech
  44. 8.8.1 Janssen Biotech Company Information
  45. 8.8.2 Janssen Biotech Business Overview
  46. 8.8.3 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  48. 8.8.5 Janssen Biotech Recent Developments
  49. 8.9 Exelixis
  50. 8.9.1 Exelixis Company Information
  51. 8.9.2 Exelixis Business Overview
  52. 8.9.3 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  54. 8.9.5 Exelixis Recent Developments
  55. 8.10 Eisai
  56. 8.10.1 Eisai Company Information
  57. 8.10.2 Eisai Business Overview
  58. 8.10.3 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  60. 8.10.5 Eisai Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 AstraZeneca.
  74. 8.13.1 AstraZeneca. Company Information
  75. 8.13.2 AstraZeneca. Business Overview
  76. 8.13.3 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  78. 8.13.5 AstraZeneca. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Small Molecule Multi-target Angiogenesis Inhibitor Value Chain Analysis
  2. 9.1.1 Small Molecule Multi-target Angiogenesis Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Small Molecule Multi-target Angiogenesis Inhibitor Production Mode & Process
  6. 9.2 Small Molecule Multi-target Angiogenesis Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Small Molecule Multi-target Angiogenesis Inhibitor Distributors
  9. 9.2.3 Small Molecule Multi-target Angiogenesis Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst